Co-Diagnostics, Inc 8-K, filed Jul 9, 2021
Co-Diagnostics, Inc. (CODX)
About this 8-K
Co-Diagnostics, Inc filed this 8-K on July 9, 2021, reporting on events of July 8, 2021.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITEDSTATES
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM8-K
CURRENTREPORT
Pursuantto Section 13 or 15(d) of the
SecuritiesExchange Act of 1934
Date of report (Date of earliest event reported): July 8, 2021
CO-DIAGNOSTICS,INC.
(Exact name of small business issuer as specified in its charter)
| Utah | 1-38148 | 46-2609363 |
|---|---|---|
| (State<br> or other jurisdiction of | (Commission | (IRS<br> Employer |
| incorporation<br> or organization) | File<br> Number) | Identification<br> Number) |
2401S. Foothill Drive, Suite D, Salt Lake City, Utah 84109
(Address of principal executive offices)
(801)438-1036
(Issuer’s telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| [<br> ] | Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| [<br> ] | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [<br> ] | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [<br> ] | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title<br> of each class | Trading<br> Symbol(s) | Name<br> of each exchange on which registered |
|---|---|---|
| Common<br> Stock, $0.001 par value | CODX | Nasdaq<br> Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [X]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements ofCertain Officers.
On July 8, 2021, Mr. Reed L. Benson resigned as the Corporate Secretary of Co-Diagnostics, Inc., a Utah corporation (the “Company”). Mr. Benson had served as the Company’s Corporate Secretary since its inception in April 2013. Mr. Benson’s resignation as Corporate Secretary was not the result of any disagreement with the Company’s management or Board of Directors relating to the Company’s operations, policies, or practices. Mr. Benson will remain an employee of the Company in the role of general counsel.
On July 8, 2021, the Company’s Board of Directors appointed Brian L. Brown, CPA, as the Company’s Corporate Secretary. As previously reported in a Form 8-K filed by the Company on February 22, 2021, Mr. Brown was appointed as the Company’s Chief Financial Officer on February 22, 2021, and will remain in such position.
There no compensatory plan, contract, or arrangement (whether or not written) entered into between the Company and Mr. Brown relating to his appointment as Corporate Secretary.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| CO-DIAGNOSTICS, INC. | |
|---|---|
| By: | /s/ Dwight H. Egan |
| Name: | Dwight<br> H. Egan |
| Title: | Chief<br> Executive Officer |
Date: July 9, 2021